ppar-alpha glucocorticoid receptor synergize promote erythroid progenitor self-renewal 
many acute chronic anaemias including haemolysis sepsis genetic bone marrow failure diseases diamond-blackfan anaemia treatable erythropoietin epo colony-forming unit erythroid progenitors cfu-es respond epo either number sensitive enough epo maintain sufficient red blood cell production- treatment anaemias requires drug acts earlier stage red cell formation enhances formation epo-sensitive cfu-e progenitors recently showed glucocorticoids specifically stimulate self-renewal early erythroid progenitor burst-forming unit erythroid bfu-e increase production terminally differentiated erythroid cells show activation peroxisome proliferator-activated receptor alpha ppar-alpha ppar-alpha agonists gw7647 fenofibrate synergizes glucocorticoid receptor gr promote bfu-e self-renewal time agonists greatly increase production mature red blood cells cultures mouse fetal liver bfu-es mobilized human adult cd34+ peripheral blood progenitors new effective culture system used human cells generates normal enucleated reticulocytes although ppara-/- mice show haematological difference wild-typemice normal phenylhydrazine phz-induced stress erythropoiesis ppar-alpha agonists facilitate recovery wild-type ppara-/- mice phz-induced acute haemolytic anaemia also show ppar-alpha alleviates anaemia mouse model chronic anaemia finally control corticosteroid treated bfu-e cells ppar-alpha co-occupies many chromatin sites gr activated ppar-alpha agonists additional ppar-alpha recruited gr-adjacent sites presumably facilitates gr-dependent bfu-e self-renewal discovery role ppar-alpha agonists stimulating self-renewal early erythroid progenitor cells suggests clinically tested ppar-alpha agonists used may improve efficacy corticosteroids treating epo-resistant anaemias 
